PFS significantly higher with nivolumab, doxorubicin, vinblastine, and dacarbazine versus brentuximab vedotin-AVD.

The 3-year PFS rates were 91% for the N-AVD group and 82% for the BV-AVD group. For patients with advanced-stage classic Hodgkin lymphoma (cHL), an updated analysis of the S1826 study showed a ...

AVADA Group (ASX:AVD) has had a great run on the share market with its stock up by a significant 40% over the last week. However, we wonder if the company's inconsistent financials would have any ...

Return On Capital Employed (ROCE): What Is It? Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested ...

Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

Opdivo plus AVD showed superior PFS and EFS compared to Adcetris plus AVD in patients with advanced Hodgkin lymphoma. The Opdivo regimen had a better side effect profile, with fewer severe side ...

Adding nivolumab (Opdivo) instead of brentuximab vedotin (Adcetris) to the standard chemotherapy backbone of doxorubicin (Adriamycin), vinblastine, and dacarbazine (AVD) resulted in longer progression ...

Patients with advanced classical Hodgkin lymphoma treated with first line brentuximab vedotin (Adcetris) plus chemotherapy showed substantial improvements in overall survival compared with those ...

Adcetris plus doxorubicin, vinblastine and dacarbazine is the first regimen to improve overall survival compared to the current standard of care for patients with advanced-stage classical Hodgkin ...

The standard-of-care chemotherapy regimen for patients with previously untreated Hodgkin lymphoma, consisting of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD), has not changed in several ...